{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T07:47:47Z","timestamp":1781855267670,"version":"3.54.5"},"reference-count":56,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007128","name":"Shaanxi Province Natural Science Foundation","doi-asserted-by":"publisher","award":["2024JC-YBMS-795"],"award-info":[{"award-number":["2024JC-YBMS-795"]}],"id":[{"id":"10.13039\/501100007128","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031935","name":"Xi&apos;an Jiaotong University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031935","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272782"],"award-info":[{"award-number":["82272782"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Analysis"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jpha.2025.101322","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T19:21:35Z","timestamp":1745608895000},"page":"101322","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["From foe to friend: Rewiring oncogenic pathways through artificial selenoprotein to combat immune-resistant tumor"],"prefix":"10.1016","volume":"15","author":[{"given":"Weiming","family":"You","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4875-6838","authenticated-orcid":false,"given":"Zhengjun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanfeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6468-6003","authenticated-orcid":false,"given":"Jin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpha.2025.101322_bib1","article-title":"Angiogenic signaling pathways and anti-angiogenic therapy for cancer","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jpha.2025.101322_bib2","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.tcb.2019.08.005","article-title":"Information theory: New look at oncogenic signaling pathways","volume":"29","author":"Zieli\u0144ska","year":"2019","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.jpha.2025.101322_bib3","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/nrc3430","article-title":"MDM2, MDMX and p53 in oncogenesis and cancer therapy","volume":"13","author":"Wade","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jpha.2025.101322_bib4","first-page":"5762","article-title":"Therapeutic opportunities in cancer therapy: Targeting the p53-MDM2\/MDMX interactions","volume":"11","author":"Munisamy","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.jpha.2025.101322_bib5","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1158\/0008-5472.CAN-21-0145","article-title":"Mdm2 and MdmX: Partners in p53 destruction","volume":"81","author":"Manfredi","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.jpha.2025.101322_bib6","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: Chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.jpha.2025.101322_bib7","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ymthe.2019.11.019","article-title":"cAMP\/EPAC signaling enables ETV2 to induce endothelial cells with high angiogenesis potential","volume":"28","author":"Kim","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jpha.2025.101322_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12041009","article-title":"Personalized medicine: Recent progress in cancer therapy","volume":"12","author":"Gambardella","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jpha.2025.101322_bib9","first-page":"197","article-title":"CRISPR-Cas9 therapeutics in cancer: Promising strategies and present challenges","volume":"1866","author":"Yi","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jpha.2025.101322_bib10","first-page":"1694","article-title":"PROTACs for BRDs proteins in cancer therapy: A review, J. Enzyme Inhib","volume":"37","author":"Wang","year":"2022","journal-title":"Med. Chem."},{"key":"10.1016\/j.jpha.2025.101322_bib11","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1126\/science.1234852","article-title":"Growing self-organizing mini-guts from a single intestinal stem cell: Mechanism and applications","volume":"340","author":"Sato","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.jpha.2025.101322_bib12","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1158\/2159-8290.CD-14-1490","article-title":"Endoplasmic reticulum stress-activated cell reprogramming in oncogenesis","volume":"5","author":"Chevet","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.jpha.2025.101322_bib13","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.semcancer.2022.10.004","article-title":"Reprogramming of glycolysis by chemical carcinogens during tumor development","volume":"87","author":"D'Souza","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.jpha.2025.101322_bib14","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41586-023-06348-2","article-title":"Rewiring cancer drivers to activate apoptosis","volume":"620","author":"Gourisankar","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jpha.2025.101322_bib15","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.tips.2013.04.007","article-title":"Targeting protein-protein interactions as an anticancer strategy","volume":"34","author":"Ivanov","year":"2013","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.jpha.2025.101322_bib16","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.coph.2013.05.009","article-title":"Protein-protein interactions as druggable targets: Recent technological advances","volume":"13","author":"Higueruelo","year":"2013","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.jpha.2025.101322_bib17","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/nrd4366","article-title":"Phenotypic screening in cancer drug discovery \u2013 past, present and future","volume":"13","author":"Moffat","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jpha.2025.101322_bib18","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-09692-y","article-title":"Network-based prediction of drug combinations","volume":"10","author":"Cheng","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jpha.2025.101322_bib19","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nchembio.1897","article-title":"Translating biosynthetic gene clusters into fungal armor and weaponry","volume":"11","author":"Keller","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.jpha.2025.101322_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2021.01.019","article-title":"Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression","volume":"184","author":"Qi","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.jpha.2025.101322_bib21","article-title":"Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer","volume":"6","author":"Wu","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jpha.2025.101322_bib22","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/4598195","article-title":"Tumorigenic cell reprogramming and cancer plasticity: Interplay between signaling, microenvironment, and epigenetics","volume":"2018","author":"Poli","year":"2018","journal-title":"Stem Cells Int."},{"key":"10.1016\/j.jpha.2025.101322_bib23","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.cell.2009.02.024","article-title":"Principles of cancer therapy: Oncogene and non-oncogene addiction","volume":"136","author":"Luo","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.jpha.2025.101322_bib24","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1146\/annurev.immunol.25.022106.141609","article-title":"Immunosuppressive strategies that are mediated by tumor cells","volume":"25","author":"Rabinovich","year":"2007","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jpha.2025.101322_bib25","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.cell.2017.01.016","article-title":"The principles of engineering immune cells to treat cancer","volume":"168","author":"Lim","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.jpha.2025.101322_bib26","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jpha.2025.101322_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-019-0339-7","article-title":"Recent advances in the CRISPR genome editing tool set","volume":"51","author":"Moon","year":"2019","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.jpha.2025.101322_bib28","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2015.37","article-title":"Off-target effects in CRISPR\/Cas9-mediated genome engineering","volume":"4","author":"Zhang","year":"2015","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.jpha.2025.101322_bib29","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.cell.2014.09.014","article-title":"CRISPR-Cas9 knockin mice for genome editing and cancer modeling","volume":"159","author":"Platt","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.jpha.2025.101322_bib30","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1021\/acsmedchemlett.9b00597","article-title":"PROTAC technology: Opportunities and challenges","volume":"11","author":"Gao","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.jpha.2025.101322_bib31","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.cbpa.2017.05.016","article-title":"Targeted protein knockdown using small molecule degraders","volume":"39","author":"Raina","year":"2017","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.jpha.2025.101322_bib32","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.1073\/pnas.0900947106","article-title":"Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX","volume":"106","author":"Pazgier","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.jpha.2025.101322_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.101037","article-title":"Rewiring chaperone-mediated autophagy in cancer by a prion-like chemical inducer of proximity to counteract adaptive immune resistance","volume":"73","author":"Yan","year":"2024","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.jpha.2025.101322_bib34","article-title":"Resetting the Hsc70-mediated lysosomal degradation of PD-L1 via a supramolecular meso peptide for the restoration of acquired anti-tumor T cell immunity","volume":"23","author":"Zhao","year":"2025","journal-title":"J. Nanotechnology"},{"key":"10.1016\/j.jpha.2025.101322_bib35","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jconrel.2020.06.041","article-title":"Resurrecting a p53 peptide activator-An enabling nanoengineering strategy for peptide therapeutics","volume":"325","author":"He","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jpha.2025.101322_bib36","article-title":"TrkA promotes MDM2-mediated AGPS ubiquitination and degradation to trigger prostate cancer progression","volume":"43","author":"Zhang","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.jpha.2025.101322_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0051426","article-title":"Molecular mechanism of mutant p53 stabilization: The role of HSP70 and MDM2","volume":"7","author":"Wiech","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jpha.2025.101322_bib38","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1158\/1541-7786.MCR-10-0534","article-title":"Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells","volume":"9","author":"Li","year":"2011","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.jpha.2025.101322_bib39","doi-asserted-by":"crossref","first-page":"762","DOI":"10.20517\/cdr.2022.18","article-title":"An overview of resistance to chemotherapy in osteosarcoma and future perspectives","volume":"5","author":"Garcia-Ortega","year":"2022","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.jpha.2025.101322_bib40","article-title":"AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing","volume":"6","author":"Sahin","year":"2020","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.jpha.2025.101322_bib41","doi-asserted-by":"crossref","first-page":"8513","DOI":"10.7150\/thno.47243","article-title":"A general-purpose Nanohybrid fabricated by Polymeric Au(I)-peptide precursor to wake the function of Peptide Therapeutics","volume":"10","author":"Yan","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.jpha.2025.101322_bib42","doi-asserted-by":"crossref","first-page":"5844","DOI":"10.1021\/acs.nanolett.0c01757","article-title":"Chiral protein supraparticles for tumor suppression and synergistic immunotherapy: An enabling strategy for bioactive supramolecular chirality construction","volume":"20","author":"Yan","year":"2020","journal-title":"Nano Lett."},{"key":"10.1016\/j.jpha.2025.101322_bib43","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jare.2022.05.009","article-title":"Turning chiral peptides into a racemic supraparticle to induce the self-degradation of MDM2","volume":"45","author":"Yang","year":"2023","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.jpha.2025.101322_bib44","article-title":"Reinvigoration of cytotoxic T lymphocytes in microsatellite instability-high colon adenocarcinoma through lysosomal degradation of PD-L1","volume":"15","author":"Liu","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jpha.2025.101322_bib45","article-title":"Hsc70 promotes anti-tumor immunity by targeting PD-L1 for lysosomal degradation","volume":"15","author":"Xu","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jpha.2025.101322_bib46","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.immuni.2024.03.020","article-title":"Jagged2 targeting in lung cancer activates anti-tumor immunity via Notch-induced functional reprogramming of tumor-associated macrophages","volume":"57","author":"Mandula","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.jpha.2025.101322_bib47","first-page":"4858","article-title":"Liposomal STAT3-degrading PROTAC prodrugs promote anti-hepatocellular carcinoma immunity via chemically reprogramming cancer stem cells","volume":"24","author":"Wang","year":"2024","journal-title":"Nano Lett."},{"key":"10.1016\/j.jpha.2025.101322_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.127055","article-title":"Gene-editing technology, from macromolecule therapeutics to organ transplantation: Applications, limitations, and prospective uses","volume":"253","author":"Harisa","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.jpha.2025.101322_bib49","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0065-2571(00)00013-3","article-title":"The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting","volume":"41","author":"Maeda","year":"2001","journal-title":"Adv. Enzym. Regul."},{"key":"10.1016\/j.jpha.2025.101322_bib50","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202416006","article-title":"Intracellular redox environment determines cancer-normal cell selectivity of selenium nanoclusters","volume":"64","author":"Xiong","year":"2025","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.jpha.2025.101322_bib51","article-title":"Targeted protein degradation: Mechanisms, strategies and application","volume":"7","author":"Zhao","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jpha.2025.101322_bib52","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ccell.2025.02.014","article-title":"Targeting tumor monocyte-intrinsic PD-L1 by rewiring STING signaling and enhancing STING agonist therapy","volume":"43","author":"Song","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jpha.2025.101322_bib53","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1038\/s41588-023-01515-7","article-title":"Systematic profiling of conditional pathway activation identifies context-dependent synthetic lethalities","volume":"55","author":"Chang","year":"2023","journal-title":"Nat. Genet."},{"key":"10.1016\/j.jpha.2025.101322_bib54","article-title":"Industrial-level production of ultrastable selenium nanoparticles using a confined coordination synthetic strategy, Cell Rep","volume":"5","author":"He","year":"2024","journal-title":"Phys. Sci."},{"key":"10.1016\/j.jpha.2025.101322_bib55","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/1097-0282(2000)55:3<227::AID-BIP50>3.0.CO;2-7","article-title":"Large-scale synthesis of peptides","volume":"55","author":"Andersson","year":"2000","journal-title":"Biopolymers"},{"key":"10.1016\/j.jpha.2025.101322_bib56","article-title":"A review of selenium (Se) nanoparticles: From synthesis to applications, Part. Part","volume":"40","author":"Huang","year":"2023","journal-title":"Syst. Charact."}],"container-title":["Journal of Pharmaceutical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S209517792500139X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S209517792500139X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:14:29Z","timestamp":1777623269000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S209517792500139X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":56,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S209517792500139X"],"URL":"https:\/\/doi.org\/10.1016\/j.jpha.2025.101322","relation":{},"ISSN":["2095-1779"],"issn-type":[{"value":"2095-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From foe to friend: Rewiring oncogenic pathways through artificial selenoprotein to combat immune-resistant tumor","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpha.2025.101322","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of Xi\u2019an Jiaotong University.","name":"copyright","label":"Copyright"}],"article-number":"101322"}}